about
An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmissionAnalysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolutionNaturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralizationDifferential activation of killer cells in the circulation and the lung: a study of current smoking status and chronic obstructive pulmonary disease (COPD).Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.Altered effector function of peripheral cytotoxic cells in COPD.Human Adaptation of Ebola Virus during the West African Outbreak.The role of neutralizing antibodies in hepatitis C virus infection.The role of humoral innate immunity in hepatitis C virus infection.A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.Flexible and rapid construction of viral chimeras applied to hepatitis C virus.Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals.An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule.Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin.Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?Quantitative Validation and Comparison of Multiplex Cytokine KitsImmunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodiesAntigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect CellsStandardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp)Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic virusesHepatitis C Virus Vaccine: Challenges and ProspectsInFusion Cloning for the Generation of Biologically Relevant HCV Chimeric Molecular ClonesCloning and Analysis of Authentic Patient-Derived HCV E1/E2 GlycoproteinsStructure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization
P50
Q27684354-9B6CAEA3-1601-4A11-A8ED-DDE8366D3BD0Q28659586-570F7D55-903F-4B20-8723-1F2772F8099EQ28731355-2EF313BB-51DF-4FDC-AECE-D03A6D3207DBQ34625924-96D48D09-E8CC-4AD4-B26E-A55370F46A09Q34683447-3FB8C969-3C4C-4BBC-A2EC-F0A22D687029Q35076885-3F3FBB54-09E6-4CCB-8385-3679B7F4F04FQ35828072-CE54EC46-472C-4B88-9C1B-F1E8517D03A5Q37250873-B8AB094C-641D-4B96-AC03-06391F54D43FQ37402042-B43255C1-7EB6-4BF7-A3F1-B32FAA841E49Q37952157-2A24CC44-0391-439E-83D2-1296D05461CCQ37987129-5482DC30-E32B-4727-B302-E77F98D6131DQ38809451-9D520B6B-22AE-40C0-BDEB-572696C2EC32Q40098163-061BA1E1-6227-45A2-9977-0731911FB243Q40688888-0CAD5210-747B-4893-A5F0-E6974408BDBDQ40757862-6BD62184-2495-4913-9A03-A3185B693C67Q41033958-30E140C6-7ED5-449C-80B4-2E25C241485BQ41041346-B10B6096-CEBB-4208-ADEF-3D97E569C8FDQ42217086-6D1B2BC5-A80B-42DC-8712-99FB7BA347C5Q45001535-7683BD7B-AE61-4670-BD8F-C4809E3C6319Q45325612-D0BD77FF-487D-4048-8701-A24E4F298810Q57203281-08EE8B71-A9F4-490F-A72C-9AEA2AC0D637Q57203286-4648DFCD-773B-44EC-A495-2FF557DF906BQ59352613-C53060D3-2F7B-4F0E-98C6-5F37F15A2818Q64066274-AC131190-1247-4C96-9926-9CB03A366F9FQ64235940-C8A3FE2B-3949-4E2C-980C-97DCC32FF19BQ64360347-CEEC46B8-1960-4F54-BA4B-93417D2BDDFFQ89805424-B7BA5C32-357D-41D2-A4B9-4A4986A3BA75Q90797502-6FE94D4C-53BD-4A63-9CC7-6E7B7E834762Q90797595-B8AE57F6-0D22-4AD3-B71B-66F050EDABF4Q95627344-CD2C8FD1-46EE-48B3-9172-C48A0C01947D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Richard A. Urbanowicz
@ast
Richard A. Urbanowicz
@en
Richard A. Urbanowicz
@es
Richard A. Urbanowicz
@sl
type
label
Richard A. Urbanowicz
@ast
Richard A. Urbanowicz
@en
Richard A. Urbanowicz
@es
Richard A. Urbanowicz
@sl
prefLabel
Richard A. Urbanowicz
@ast
Richard A. Urbanowicz
@en
Richard A. Urbanowicz
@es
Richard A. Urbanowicz
@sl
P106
P1153
24068012100
P21
P31
P496
0000-0002-2461-4993